Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

34.01 +0.25 (+0.74%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	837,269
Open	33.30
Bid (Size)	32.63 (400)
Ask (Size)	34.98 (100)
Prev. Close	33.76
Today's Range	32.53 - 34.12
52wk Range	12.15 - 39.96
Shares Outstanding	105,341,296
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What to Know About This Fund’s $50 Million Exit From Ascendis Pharma ↗

Today 15:05 EDT

Ascendis Pharma develops long-acting therapies for rare endocrine and pediatric diseases using its proprietary TransCon technology.

Via The Motley Fool

This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗

Today 14:57 EDT

Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach.

Via The Motley Fool

Performance

YTD	+43.2%	+43.2%
1 Month	+2.6%	+2.6%
3 Month	+12.0%	+12.0%
6 Month	+66.6%	+66.6%
1 Year	+133.7%	+133.7%

More News

Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700% ↗

Today 14:51 EDT

Via The Motley Fool

Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten ↗

May 07, 2026

Via Chartmill

Why Edgewise Therapeutics Stock Topped the Market on Tuesday ↗

March 17, 2026

Via The Motley Fool

This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares ↗

March 15, 2026

Via The Motley Fool

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗

March 15, 2026

Via The Motley Fool

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗

February 20, 2026

Via The Motley Fool

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗

February 19, 2026

Via The Motley Fool

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗

February 19, 2026

Via The Motley Fool

This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗

February 19, 2026

Via The Motley Fool

CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗

February 19, 2026

Via The Motley Fool

BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗

February 19, 2026

Via The Motley Fool

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗

February 17, 2026

Via Stocktwits

Why Edgewise Therapeutics Stock Crushed the Market on Monday ↗

February 09, 2026

Via The Motley Fool

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

Via The Motley Fool

Why Edgewise Therapeutics Stock Rocked the Market Today ↗

December 24, 2025

Via The Motley Fool

Let's take a look at the stocks that are in motion in today's session. ↗

December 24, 2025

Via Chartmill

Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout ↗

December 24, 2025

Via Stocktwits

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

Via MarketMinute

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

Via The Motley Fool

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

Via The Motley Fool

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

Via The Motley Fool

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Via The Motley Fool

Frequently Asked Questions

Is Edgewise Therapeutics, Inc. - Common Stock publicly traded?

Yes, Edgewise Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Edgewise Therapeutics, Inc. - Common Stock trade on?

Edgewise Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Edgewise Therapeutics, Inc. - Common Stock?

The ticker symbol for Edgewise Therapeutics, Inc. - Common Stock is EWTX on the Nasdaq Stock Market

What is the current price of Edgewise Therapeutics, Inc. - Common Stock?

The current price of Edgewise Therapeutics, Inc. - Common Stock is 34.01

When was Edgewise Therapeutics, Inc. - Common Stock last traded?

The last trade of Edgewise Therapeutics, Inc. - Common Stock was at 05/14/26 04:00 PM ET

What is the market capitalization of Edgewise Therapeutics, Inc. - Common Stock?

The market capitalization of Edgewise Therapeutics, Inc. - Common Stock is 3.58B

How many shares of Edgewise Therapeutics, Inc. - Common Stock are outstanding?

Edgewise Therapeutics, Inc. - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.